IL17A and systemic lupus erythematosus: Beyond the inhibition of TLR signaling, experimental evidence showed that HCQ reduces the concentration of proatherogenic cytokines, such as IFNα, IL6, TNF-α, IL17, and IL22, in SLE patients through different mechanisms [105, 106].